Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer's disease: an 11-year follow-up study.
Alzheimer’s disease
ApoE
cognitive disorders and dementia
risk factors
subjective cognitive decline
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
26
07
2019
accepted:
06
02
2020
pubmed:
12
2
2020
medline:
22
6
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
Subjective cognitive decline (SCD) is a self-experienced decline in cognitive capacity with normal performance on standardized cognitive tests and has been shown to increase the risk of Alzheimer's disease (AD). SCD could also be related to other conditions such as normal aging, psychiatric, neurological or medical disorders. The SCD Initiative proposed a set of features (SCD-plus) that increase the likelihood of preclinical AD in individuals with SCD. Our aim was to assess the effect of these features on the risk of conversion from SCD to AD. In total 150 SCD subjects who underwent extensive neuropsychological investigation, assessment of cognitive complaints and apolipoprotein E (ApoE) genotyping at baseline and clinical-neuropsychological follow-up for a mean time of 11 years were included. During the follow-up, 20 subjects developed AD. Considering SCD-plus features, age at onset ≥60 years and ApoE ε4 significantly increased the risk of conversion from SCD to AD. When our sample was stratified into three groups (no risk factor, one risk factor, two risk factors), the proportion of conversion was statistically significantly different between the three groups. Our model allows the risk of AD to be stratified in patients experiencing SCD according to age at onset and ApoE genotype.
Sections du résumé
BACKGROUND AND PURPOSE
Subjective cognitive decline (SCD) is a self-experienced decline in cognitive capacity with normal performance on standardized cognitive tests and has been shown to increase the risk of Alzheimer's disease (AD). SCD could also be related to other conditions such as normal aging, psychiatric, neurological or medical disorders. The SCD Initiative proposed a set of features (SCD-plus) that increase the likelihood of preclinical AD in individuals with SCD. Our aim was to assess the effect of these features on the risk of conversion from SCD to AD.
METHODS
In total 150 SCD subjects who underwent extensive neuropsychological investigation, assessment of cognitive complaints and apolipoprotein E (ApoE) genotyping at baseline and clinical-neuropsychological follow-up for a mean time of 11 years were included.
RESULTS
During the follow-up, 20 subjects developed AD. Considering SCD-plus features, age at onset ≥60 years and ApoE ε4 significantly increased the risk of conversion from SCD to AD. When our sample was stratified into three groups (no risk factor, one risk factor, two risk factors), the proportion of conversion was statistically significantly different between the three groups.
CONCLUSIONS
Our model allows the risk of AD to be stratified in patients experiencing SCD according to age at onset and ApoE genotype.
Substances chimiques
Apolipoprotein E4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
894-899Subventions
Organisme : Ministero della Salute and Regione Toscana
ID : GR-2010-2316359
Pays : International
Informations de copyright
©2020 European Academy of Neurology.
Références
Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014; 10: 844-852.
Eckerström M, Göthlin M, Rolstad S, et al. Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample. Alzheimers Dement 2017; 8: 96-107.
Mazzeo S, Padiglioni S, Bagnoli S, et al. The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study. J. Neurol 2019; 266: 487-497.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association, 2013.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
Crook TH, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr 1992; 4: 165-176.
Bracco L, Amaducci L, Pedone D, et al. Italian multicentre study on dementia (SMID): a neuropsychological test battery for assessing Alzheimer's disease. J Psychiatr Res 1990; 24: 213-226.
Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002; 22: 443-447.
Baddeley A, Della Sala S, Papagno C, Spinnler H. Dual-task performance in dysexecutive and nondysexecutive patients with a frontal lesion. Neuropsychology 1997; 11: 187-194.
Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici: Gruppo Italiano per lo studio neuropsicologico dell'invecchiamento. Milano: Masson Ital Period, 1987.
Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 1996; 17: 305-309.
Brazzelli M, Della Sala S, Laiacona M. Calibration of the Italian version of the Rivermead behavioural memory test: a test for the ecological evaluation of memory. Boll Psicol Appl 1993: 33-42.
Colombo L, Sartori G, Brivio C. Stima del quoziente intellettivo tramite l'applicazione del TIB (Test Breve di Intelligenza). G Ital Psicol 2002; 3: 613-638.
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
Scarabino D, Gambina G, Broggio E, Pelliccia F, Corbo RM. Influence of family history of dementia in the development and progression of late-onset Alzheimer's disease. Am J Med Genet Part B Neuropsychiatr Genet 2016; 171B: 250-256.
Slot RER, Verfaillie SCJ, Overbeek JM, et al. Subjective cognitive impairment cohort (SCIENCe): study design and first results. Alzheimer's Res Ther 2018; 10: 76.
Hong YJ, Yoon B, Shim YS, et al. Predictors of clinical progression of subjective memory impairment in elderly subjects: data from the clinical research centers for dementia of South Korea (CREDOS). Dement Geriatr Cogn Disord 2015; 40: 158-165.
Rawle MJ, Davis D, Bendayan R, Wong A, Kuh D, Richards M. Apolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course. Transl Psychiatry 2018; 8: 18.
Bessi V, Mazzeo S, Padiglioni S, et al. Subjective cognitive decline to Alzheimer's disease: the predictive role of neuropsychological assessment, personality traits, and cognitive reserve. A 7-Year Follow-Up Study. J Alzheimers Dis 2018; 63: 1523-1535.